Details of the Drug Combination

General Information of Drug Combination (ID: DC7EHVI)

Drug Combination Name

Amonafide Vincristine

Indication

Disease Entry	Status	REF
Invasive ductal carcinoma	Investigative	[1]

Component Drugs

Amonafide DMAH59S

Vincristine DMINOX3

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: BT-549

Zero Interaction Potency (ZIP) Score: 2.15

Bliss Independence Score: 3.37

Loewe Additivity Score: 4.74

LHighest Single Agent (HSA) Score: 6.8

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Amonafide

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Phase 3	[2]
Ovarian cancer	2C73	Phase 3	[2]
Prostate cancer	2C82.0	Phase 3	[2]

Indication(s) of Vincristine

Disease Entry	ICD 11	Status	REF
Acute lymphoblastic leukaemia	2A85	Approved	[3]
Adult kidney Wilms tumor	N.A.	Approved	[4]
Beckwith-Wiedemann syndrome	N.A.	Approved	[4]
Burkitt lymphoma	N.A.	Approved	[4]
Central nervous system neoplasm	N.A.	Approved	[4]
Childhood acute lymphoblastic leukemia	N.A.	Approved	[4]
Childhood kidney Wilms tumor	N.A.	Approved	[4]
Hamartoma	N.A.	Approved	[4]
Kidney neoplasm	N.A.	Approved	[4]
Leukemia	N.A.	Approved	[4]
MALT lymphoma	N.A.	Approved	[4]
Nodal marginal zone lymphoma	2A85.0	Approved	[4]
Plasma cell myeloma	2A83.1	Approved	[4]
Primitive neuroectodermal tumor	N.A.	Approved	[4]
Splenic marginal zone lymphoma	N.A.	Approved	[4]
Testicular lymphoma	N.A.	Approved	[4]
Wilms tumor	N.A.	Approved	[4]
Classic Hodgkin lymphoma	N.A.	Investigative	[4]
Follicular lymphoma	2A80	Investigative	[4]
Neuroblastoma	2D11.2	Investigative	[4]

Vincristine Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Tubulin beta (TUBB)	TTYFKSZ	NOUNIPROTAC	Modulator	[5]
------------------------------------------------------------------------------------

Vincristine Interacts with 4 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
Multidrug resistance-associated protein 1 (ABCC1)	DTSYQGK	MRP1_HUMAN	Substrate	[6]
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[7]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[8]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[9]
------------------------------------------------------------------------------------

Vincristine Interacts with 3 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[10]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Metabolism	[10]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Metabolism	[11]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adenocarcinoma	DCOVWI2	DU-145	Investigative	[12]
Adenocarcinoma	DCFMQZ0	A549	Investigative	[12]
Adenocarcinoma	DCVFX46	SW-620	Investigative	[12]
Adenocarcinoma	DCZ1STM	HCT116	Investigative	[12]
Adenocarcinoma	DCGARNE	HCT-15	Investigative	[12]
Adult T acute lymphoblastic leukemia	DCDPHB1	MOLT-4	Investigative	[12]
Astrocytoma	DCK4QWA	U251	Investigative	[12]
Clear cell renal cell carcinoma	DC2HR4A	786-0	Investigative	[12]
Clear cell renal cell carcinoma	DCS8I24	A498	Investigative	[12]
Cutaneous melanoma	DCHLWSL	SK-MEL-5	Investigative	[12]
Glioma	DC4K52B	SF-268	Investigative	[12]
Large cell lung carcinoma	DCOE57D	NCI-H460	Investigative	[12]
Lung adenocarcinoma	DCC6WVF	HOP-62	Investigative	[12]
Non-small cell lung carcinoma	DCMBB49	HOP-92	Investigative	[12]
Papillary renal cell carcinoma	DCY319L	ACHN	Investigative	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 15 DrugCom(s)

References

1	Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
2	ClinicalTrials.gov (NCT00715637) Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDEStudy. U.S. National Institutes of Health.
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6785).
4	Vincristine FDA Label
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6	Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). Eur J Pharmacol. 2008 Sep 4;591(1-3):128-31.
7	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
8	L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines. Toxicol Lett. 2010 Feb 15;192(3):408-18.
9	Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
10	Association of CYP3A5 expression and vincristine neurotoxicity in pediatric malignancies in Turkish population. J Pediatr Hematol Oncol. 2017 Aug;39(6):458-462.
11	Drug Interactions Flockhart Table
12	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.